Nanoform Finland Plc, a medicine performance enhancing company, completed the First Subject First Visit (FSFV) in a trial to evaluate the relative bioavailability of its nanocrystalline enabled alternative to an amorphous solid dispersion (ASD) formulation of nanoenzalutamide and Xtandi, an androgen receptor inhibitor to treat prostate cancer. The single-dose, randomized, comparative bioavailability study, which is performed by a contract research organization (CRO) in North America, compares...